Compare Vanguard Total World Stock Index Fund ETF (VT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total World Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total World Stock Index Fund ETF trades at $161.64, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VT | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $161.30 | $164.28 |
52-Week Low | $132.19 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VT trades at $161.53, up 0.35% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The ETF offers global diversification across over 10,000 stocks with a low 0.06% expense ratio, though RSI levels suggest short-term overbought conditions. Recent institutional activity includes mixed positioning changes, such as Barry Investment Advisors reducing holdings by 18.7% in Q2 2026 (SEC filing, August 10, 2026).
Outlook remains positive for long-term investors seeking broad global exposure, supported by VT's cost efficiency and diversification benefits. Risks include trade war uncertainties highlighted in news (The Motley Fool, July 31, 2026) and potential volatility from geopolitical events. Analyst sentiment is generally favorable, with comparisons to peers emphasizing VT's lower fees and comprehensive coverage.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
